Supporting Information for:

Synthesis and reactivity of *N*-heterocyclic carbene gold(I) and gold(III) imidate complexes and their catalytic activity in 1,5-enyne cycloisomerization

Jonathan P. Reeds, § Adrian C. Whitwood, § Mark P. Healy†,‡ and Ian J. S. Fairlamb*§

§ Department of Chemistry, University of York, Heslington, York, YO10 5DD, United Kingdom.

† GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, United Kingdom.

CONTENTS

Section	Title General Experimental Details				
1.0					
2.0	Procedures and Characterization Data for Au(I) and Au(III) Complexes				
2.01	$[Au(N-succ)(I^tBu)]$ (11a)	S3			
2.02	$[Au(N-tfs)(I^tBu)]$ (11b)	S3			
2.03	$[Au(N-mal)(I^tBu)]$ (11c)	S4			
2.04	$[Au(N-ptm)(I^tBu)] (11d)$	S4			
2.05	$[Au(N-obs)(I^tBu)] (11e)$	S5			
2.06	$[AuBr(I^{t}Bu)] (11g)$	S5			
2.07	I ^t Pe.HCl	S6			
2.08	$[AuCl(I^{t}Pe)] (12f)$	S6			
2.09	$[Au(N-succ)(I^{t}Pe)] (12a)$	S6			
2.10	$[Au(N-tfs)(I^{t}Pe)] (12b)$	S7			
2.11	[Au(N-mal)(ItPe)] (12c)	S7			
2.12	$[Au(N-ptm)(I^{t}Pe)] (12d)$	S8			
2.13	$[Au(N-obs)(I^{t}Pe)] (12e)$	S 8			
2.14	$[AuBr(I^{t}Pe)] (12g)$	S9			
2.15	[Au(N-succ)(IMes)] (13a)	S9			
2.16	[Au(N-tfs)(IMes)] (13b)	S9			

Section	Title		
2.17	[Au(N-mal)(IMes)] (13c)	S10	
2.18	[Au(N-ptm)(IMes)] (13d)	S10	
2.19	[Au(N-obs)(IMes)] (13e)	S10	
2.20	[AuBr2(N-succ)(ItBu)] (18a)	S11	
2.21	$[AuBr_2(N-dbs)(I^tBu)]$ (18b)	S11	
2.22	[AuBr2(N-tfs)(ItBu)] (18c)	S12	
2.23	$[AuBr_2(N-mal)(I^tBu)]$ (18d)	S12	
2.24	$[AuBr_2(N-ptm)(I^tBu)]$ (18e)	S12	
2.25	[AuBr2(N-obs)(ItBu)] (18f)	S13	
2.26	$[AuBr_3(I^tBu)]$ (18g)	S13	
2.27	[AuBr2(N-succ)(ItPe)] (19a)	S14	
2.28	$[AuBr_2(N-dbs)(I^tPe)](19b)$	S14	
2.29	$[AuBr_2(N-tfs)(I^tPe)](19c)$	S14	
2.30	[AuBr2(N-mal)(ItPe)] (19d)	S15	
2.31	[AuBr2(N-ptm)(ItPe)] (19e)	S15	
2.32	[AuBr2(N-obs)(ItPe)] (19f)	S15	
2.33	$[AuBr_3(I^{\dagger}Pe)]$ $(\mathbf{19g})$	S16	
2.34	[AuBr2(N-succ)(IMes)] (20a)	S16	
2.35	[AuBr2(N-mal)(IMes)] (20b)	S17	
2.36	[AuBr2(N-ptm)(IMes)] (20c)	S17	
2.37	$[\mathrm{Au}(N^{\bar{1}\bar{5}}-\mathrm{succ})(\hat{\mathbf{I}}^{\bar{t}}\mathrm{Pe})] (\hat{\mathbf{I}}^{\bar{s}}N-\mathbf{12a})$	S17	
2.38	[AuBr2(15N-succ)(ItPe)] (15N-19a)	S18	
3.0	1,5-Enyne cycloisomerization catalysis	S19	
3.1	General procedure for the cycloisomerization of 4-phenyl-1-hexen-5-yne (24) – without catalyst preformation	S19	
3.2	General procedure for the cycloisomerization of 4-phenyl-1-hexen-5-yne (24) – with catalyst preformation	S19	
3.3	4-Phenyl-1-hexen-5-yne (24)	S19	
3.4	3-Phenylbicyclo[3.1.0]hex-2-ene (25)	S20	
1.0	X-Ray Crystallographic Data	S21	
5.0	References	S22	

1.0 General Experimental Details

All reactions involving silver salts were carried out in the absence of light. Dichloromethane, acetonitrile and diethyl ether were dried by passing through a column of activated alumina, tetrahydrofuran was distilled from sodium benzophenone ketyl, ethanol was distilled from sodium ethoxide, acetone was distilled from calcium chloride and dimethyl sulphoxide (DMSO) was distilled from calcium hydride. Infra-red spectra were recorded on a Unicam Research Series FT-IR spectrometer. Mass spectrometry was carried out using a Fisons Analytical (VG) Autospec instrument. ¹H, ¹³C and ¹⁹F

NMR spectra were collected on a JEOL ECX400 spectrometer operating at 400, 101 and 376 MHz, respectively, and referenced to residual solvent signals. ¹³C NMR signals are singlets unless otherwise stated. ¹⁵N NMR spectra were collected on a Bruker AMX500 spectrometer operating at 500 MHz. Gas chromatography was carried out on a Varian 430 instrument with a Factor Four Capillary column (VF-1ms, 15 m, 0.25 mm) and a flame ionisation detector. All column chromatography was performed using silica-gel (mesh 220-440) purchased from Fluka Chemicals with the solvent systems specified within the text. TLC analysis was performed using Merck 5554 aluminium backed silica plates, compounds were visualized using UV light (254 nm) and a basic aqueous solution of potassium permanganate. Mps were measured in open capillary tubes using a Stuart SMP3 Digital Melting Point Apparatus and are uncorrected. 1-Phenyl-2-propyn-1-ol, allyltrimethylsilane and AgOTf were purchased from Alfa Aesar. All other chemicals were purchased from Sigma Aldrich Inc. and used without further purification, unless otherwise stated.

2.0 Procedures and Characterization data for Au(I) and Au(III) complexes

2.01 $[Au(N-succ)(I^tBu)]$ (11a)

[AuCl(I¹Bu)] (11f) (121 mg, 294 μmol, 1 equiv.) and silver succinimidate (60.3 mg, 294 μmol, 1 equiv.) were dissolved in dichloromethane (10 ml) and stirred at room temperature for 1 hour. The suspension was filtered through CeliteTM and the filtrate reduced to dryness *in vacuo*. The resulting white powder was precipitated from dichloromethane/pentane and washed with diethyl ether to give the title compound as a white powder (122 mg, 256 μmol, 87%). ¹H NMR (400 MHz, CDCl₃) δ 7.08 (s, 2H, imidazole *CH*), 2.64 (s, 4H, succ *CH*₂), 1.89 (s, 18H, ¹Bu C(*CH*₃)₃). ¹³C NMR (400 MHz, CDCl₃) δ 188.8 (succ *C*=O), 170.8 (carbene Au-*C*), 116.4 (imidazole *C*H), 59.1 (¹Bu *C*(CH₃)₃), 31.8 (¹Bu C(*C*H₃)₃), 31.6 (succ *C*H₂). IR (CH₂Cl₂, cm⁻¹) *v*_{max} 3684 (w), 3172 (w), 3045 (w), 2972 (m), 2932 (m), 1712 (w), 1645 (s), 1458 (w), 1434 (w), 1408 (w), 1380 (w), 1352 (m), 1285 (m), 1230 (m), 1158 (w). ESI⁺-MS *m/z* 498.1 (9%, [MNa]⁺), 476.2 (100%, [MH]⁺), 420.1 (4%, [M-¹Bu+2H]⁺), 405.1 (31%), 349.1 (8%), 293.0 (3%). ESI⁺-HRMS calcd. for C₁₅H₂₅AuN₃O₂ ([MH]⁺) 476.1607; found 476.1596. Mp 230 °C (decomp.).

$2.02 [Au(N-tfs)(I^{t}Bu)] (11b)$

[AuCl(I t Bu)] (11f) (70.9 mg, 172 µmol, 1 equiv.), silver(I) oxide (24.0 mg, 103 µmol, 0.6 equiv.) and tetrafluorosuccinimide (32.5 mg, 190 µmol, 1.1 equiv.) were mixed in dichloromethane (5 ml) under an atmosphere of N_2 and stirred at room temperature for 2 hours. The suspension was filtered through CeliteTM and the filtrate reduced to dryness *in vacuo*. The resulting white powder was precipitated from

dichloromethane/pentane, washed with diethyl ether and dried *in vacuo* to give the title compound as a white powder (85.6 mg, 157 μmol, 91%). ¹H NMR (400 MHz, CDCl₃) δ 7.15 (s, 2H, imidazole C*H*), 1.88 (s, 18H, ^tBu C(C*H*₃)₃). ¹⁹F NMR (376 MHz, CDCl₃) δ -127.5 (s, tfs C*F*₂). ¹³C NMR (101 MHz, CDCl₃) δ 170.4 (m, tfs *C*=O), ¹ 167.0 (carbene Au-*C*), 116.9 (imidazole *C*H), 107.4 (tt, J = 267, 22 Hz, tfs *C*F₂), 59.2 (^tBu C(CH₃)₃), 31.8 (^tBu C(CH₃)₃). IR (CH₂Cl₂, cm⁻¹) v_{max} 3471 (w), 3196 (w), 3172 (w), 3061 (w), 2974 (m), 2360 (m), 2341 (m), 1704 (s), 1408 (m), 1400 (m), 1381 (m), 1371 (m), 1305 (s), 1269 (s), 1192 (s), 1150 (s), 1067 (m), 1016 (m). ESI⁺-MS m/z 611.1 (16%, [MNa+MeCN]⁺), 570.1 (100%, [MNa]⁺), 548.1 (1%), 445.1 (2%), 418.2 (13%). ESI⁺-HRMS calcd. for ([MNa]⁺) C₁₅H₂₀AuF₄N₃NaO₂ 570.1055; found 570.1047. Mp 166-168 °C.

2.03 [$Au(N-mal)(I^tBu)$] (11c)

A protocol similar to that used for **11a** gave the title compound as a white solid {from 120 mg, 291 μ mol, of [AuCl(I¹Bu)] (**11f**)} (128.7 mg, 272 μ mol, 93%). ¹H NMR (400 MHz, CDCl₃) δ 7.09 (s, 2H, imidazole C*H*), 6.56 (s, 2H, mal C*H*), 1.88 (s, 18H, ¹Bu C(C*H*₃)₃). ¹³C NMR (400 MHz, CDCl₃) δ 182.4 (mal *C*=O), 170.5 (carbene Au-*C*), 136.0 (mal *C*H), 116.3 (imidazole *C*H), 59.0 (¹Bu *C*(CH₃)₃), 31.8 (¹Bu C(CH₃)₃). IR (CH₂Cl₂, cm⁻¹) v_{max} 3171 (w), 3053 (m), 2973 (m), 1662 (s), 1641 (m), 1608 (w), 1567 (w), 1475 (w), 1408 (m), 1380 (m), 1370 (m), 1347 (s), 1304 (w), 1281 (w), 1234 (w), 1213 (m), 1178 (m), 1158 (w). ESI[†]-MS m/z 474.1 (100%, [MH][†]), 418.2 (8%), 181.2 (1%, [I¹BuH][†]). ESI[†]-HRMS calcd. for C₁₅H₂₃AuN₃O₂ ([MH][†]) 474.1450; found 474.1439. Mp 190 °C (decomp.). Note: 7% of a photo-dimerized product (**17a**) was observed in crude ¹H NMR spectra of this product, for which further characterization was made.

$2.04 [Au(N-ptm)(I^{t}Bu)] (11d)$

$2.05 [Au(N-obs)(I^{t}Bu)] (11e)$

[AuCl($I^{t}Bu$)] (11f) (70.9 mg, 172 µmol, 1 equiv.), silver(I) oxide (24.0 mg, 103 µmol, 0.6 equiv.), and o-benzoic sulfimide (34.7 mg, 190 µmol, 1.1 equiv.) were mixed in dichloromethane (5 ml) under an inert atmosphere and stirred at room temperature for 2 hours. The suspension was filtered through CeliteTM and the filtrate reduced to dryness in vacuo. The resulting white powder was precipitated from dichloromethane/pentane, washed with diethyl ether and dried in vacuo to give the title compound as a white powder (85.0 mg, 152 μmol, 89%). ¹H NMR (400 MHz, CDCl₃) δ 7.94-7.90 (m, 1H, obs aromatic CH), 7.85-7.81 (m, 1H, obs aromatic CH), 7.72-7.64 (m, 2H, obs aromatic CH), 7.12 (s, 2H, imidazole CH), 1.91 (s. 18H, ^tBu C(CH₃)₃). ¹³C NMR (101 MHz, CDCl₃) δ 167.5 (carbene Au-C), 166.1 (obs C=O), 141.7 (obs aromatic C), 132.9 (obs aromatic CH), 132.8 (obs aromatic CH), 131.8 (obs aromatic C), 124.1 (obs aromatic CH), 120.3 (obs aromatic CH), 116.7 (imidazole CH), 59.1 {^tBu C(CH₃)₃}, 31.8 {^tBu $C(CH_3)_3$. IR $(CH_2Cl_2, cm^{-1}) v_{max} 3364$ (m), 3172 (w), 3061 (m), 2973 (m), 1742 (m), 1689 (s) 1559 (w), 1540 (w), 1521 (w), 1459 (m), 1400 (m), 1382 (m), 1371 (m), 1338 (m), 1303 (s), 1266 (s), 1249 (s), 1212 (m), 1173 (s), 1157 (s), 1122 (m), 1057 (w), $ESI^{+}-MS$ m/z 714.5 (3%), 675.2 (3%), 582.1 (100%, $[MNa]^+$), 528.2 (2%), 435.1 (41%, $[MNa-obs+C1]^+$), 394.2 (13%, $[M-obs+NH_3]^+$), 360.3 (2%), 274.3 (1%), 172.1 (7%). ESI⁺-HRMS calcd. for C₁₈H₂₄AuN₃NaO₃S ([MNa]⁺) 582.1096; found 582.1083. Mp 150 °C (decomp.).

2.06 [AuBr(I^tBu)] (11g)

A protocol reported by de Frémont *et al.* was used.² [AuCl(I^tBu)] (11f) (105 mg, 255 μmol, 1 equiv.) and LiBr (186 mg, 2.13 mmol, 8.4 equiv.) were mixed in acetone (4 ml) at room temperature for 24 hours. The resulting solution was reduced to dryness *in vacuo* and redissolved in dichloromethane, dried (MgSO₄) and filtered through a plug of silica-gel. The volume was reduced to <0.5 ml and pentane was added resulting in a white precipitate. This was separated by filtration, washed with cold pentane and dried *in vacuo* to give the title compound as a white powder (99.2 mg, 217 μmol, 85%). ¹H NMR (400 MHz, CDCl₃) δ 7.09 (s, 2H, imidazole *CH*), 1.87 (s, 18H, ^tBu *CH*₃). ¹³C NMR (100 MHz, CDCl₃) δ 172.5 (carbene Au-*C*), 116.3 (imidazole *CH*), 59.1 (^tBu quaternary *C*), 31.8 (^tBu CH₃). ESI⁺-MS *m/z* 479.0 (2%, [MNa]⁺), 405.1 (9%, [M-Br+CO]⁺), 349.1 (21%, [M-Br-^tBu+H+CO]⁺), 293.0 (100%, [M-Br-^tBu+2H+CO]⁺), 266.0 (3%). ESI⁺-HRMS calcd. for C₁₁H₂₀AuBrN₂Na ([MNa]⁺) 479.0368; found 479.0359.

2.07 I^tPe.HCl

A protocol similar to that reported by Jafarpour *et al.*. was used.³ *tert*-Pentylamine (5.18 g, 59.4 mmol, 2 equiv.) and glyoxal (3.35 ml, 29.8 mmol, 1 equiv., 40% in water) were dissolved in ethanol (50 ml). Formic acid (4 drops) was added and the solution was stirred at room temperature for 2 days. The resulting yellow solution was reduced *in vacuo* to give a yellow oil and re-dissolved in toluene (60 ml). Paraformaldehyde (0.612 g, 20.4 µmol, 0.7 equiv.) was added and the suspension stirred at 100 °C until a clear solution formed. HCl (5.10 ml, 20.4 µmol, 0.7 equiv., 4 M in dioxane) was added at 40 °C and the solution was then stirred at 70 °C overnight. The resulting white precipitate was separated by filtration and washed with acetone to give the title product as a white powder (2.50 g, 10.2 mmol, 34%). ¹H NMR (400 MHz, CDCl₃) δ 10.45 (t, J = 2 Hz, 1H, N₂CH), 7.48 (d, J = 2 Hz, 2H, imidazole CH), 2.04 (q, J = 7.5 Hz, 4H, ¹Pe CH₂CH₃), 1.75 (s, 12H, ¹Pe C(CH₃)₂), 0.75 (t, J = 7.5 Hz, 6H, ¹Pe CH₂CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 135.3 (N₂CH), 119.7 (imidazole CH), 63.5 (¹Pe quaternary C), 35.3 (¹Pe CH₂CH₃), 27.4 {C(CH₃)₂}, 8.1 (¹Pe CH₂CH₃). IR (CH₂Cl₂, cm⁻¹) v_{max} 3657 (w), 3338 (w), 3165 (w), 3041 (w), 2972 (s), 2358 (w), 1534 (w), 1463 (m), 1386 (m), 1274 (m), 1184 (m), 1126 (m). ESI⁺-MS m/z 209.2 (100%, [MH]⁺), 139.1 (4%). ESI⁺-HRMS calcd. for C₁₃H₂₆ClN₂ ([MH]⁺) 209.2012; found 209.2014. Mp 228-230 °C.

$2.08 \left[AuCl(I^{t}Pe) \right] (12f)$

A protocol similar to that used for [AuCl(I¹Bu)] (**11f**) gave the title compound as a white solid (from 390 mg, 1.60 mmol of I¹Pe.HCl) (0.642 g, 1.46 mmol, 99%). ¹H NMR (400 MHz, CDCl₃) δ 7.04 (s, 2H, imidazole C*H*), 2.48 (q, J = 7.5 Hz, 4H, ¹Pe CH2CH₃), 1.79 (s, 12H, ¹Pe CH3), 0.64 (t, J = 7.5 Hz, 6H, ¹Pe CH2CH3). ¹³C NMR (400 MHz, CDCl₃) δ 168.1 (carbene Au-C), 117.3 (imidazole C), 61.7 (¹Pe quaternary C), 36.3 (¹Pe CH2CH₃), 29.3 (¹Pe CH2CH₃), 7.8 {¹Pe C(CH3)₂}. IR (CH2Cl₂, cm⁻¹) v_{max} 3680 (w), 3196 (w), 3172 (w), 3046 (m), 2972 (s), 2929 (m), 2880 (m), 2360 (w), 1604 (w), 1567 (w), 1460 (m), 1407 (m), 1393 (s), 1377 (s), 1339 (w), 1309 (m), 1228 (m), 1190 (s), 1152 (w). ESI¹-MS m2 463.1 (100%, [MNa]¹+), 226.9 (5%). ESI¹-HRMS calcd. for C13H24AuClN2Na ([MNa]¹+) 463.1186; found 463.1186. Mp 157-158 °C.

$2.09 \left[Au(N-succ)(I^{t}Pe) \right] (12a)$

A protocol similar to that used for **11a** gave the title compound as a white solid {from 120 mg, 269 μ mol, of [AuCl(I^tPe)] (**12f**)} (126 mg, 251 μ mol, 93%). ¹H NMR (400 MHz, CDCl₃) δ 7.05 (s, 2H, imidazole C*H*), 2.62 (s, 4H, succ C*H*₂), 2.48 (q, J = 7.5 Hz, 4H, ^tPe C*H*₂), 1.82 {s, 12H, ^tPe C(C*H*₃)₂},

0.66 (t, J = 7.5 Hz, 6H, ^tPe CH₂C H_3). ¹³C NMR (400 MHz, CDCl₃) δ 188.7 (succ C = O), 170.8 (carbene Au-C), 117.3 (imidazole CH), 61.9 (^tPe quaternary C), 36.3 (^tPe CH₂CH₃), 31.6 (succ CH₂), 29.3 (^tPe C(CH₃)₂), 7.9 (^tPe CH₂CH₃). IR (solid, cm⁻¹) v_{max} 2963 (w), 2160 (m), 2028 (m), 1631 (s), 1561 (w), 1460 (w), 1395 (w), 1378 (w), 1353 (s), 1284 (w), 1260 (w), 1227 (s), 1140 (w), 1009 (m), 817 (m), 739 (m), 703 (m), 656 (m), 621 (m). IR (CH₂Cl₂, cm⁻¹) v_{max} 3670 (w), 3172 (w), 3052 (m), 2970 (m), 2936 (m), 2880 (m), 2360 (w), 1644 (s), 1461 (m), 1435 (w), 1407 (m), 1393 (m), 1379 (m), 1352 (s), 1310 (w), 1285 (m), 1230 (s), 1191 (m). ESI⁺-MS m/z 504.2 (100%, [MH]⁺), 433.2 (21%), 363.1 (6%), 292.0 (4%), 209.2 (4%). ESI⁺-HRMS calcd. for C₁₇H₂₉AuN₃O₂ ([MH]⁺) 504.1920; found 504.1916. Mp 140-142 °C.

$2.10 [Au(N-tfs)(I^{t}Pe)] (12b)$

A protocol similar to that used for **11b** gave the title compound as a white solid {from 100 mg, 228 μmol, of [AuCl(I^tPe)] (**12f**)} (122 mg, 212 μmol, 93%). ¹H NMR (400 MHz, CDCl₃) δ 7.11 (s, 2H, imidazole *CH*), 2.48 (q, J = 7.5 Hz, 4H, ^tPe CH_2CH_3), 1.83 {s, 12H, ^tPe $C(CH_3)_2$ }, 0.69 (t, J = 7.5 Hz, 6H, ^tPe CH_2CH_3). ¹⁹F NMR (376 MHz, CDCl₃) δ -127.5 (s, CF_2). ¹³C NMR (101 MHz, CDCl₃) δ 170.4 (m, C=O), ¹ 167.5 (carbene Au-C), 117.8 (imidazole CH), 107.4 (tt, J = 267 and 22 Hz, tfs CF_2), 62.1 (^tPe quaternary C), 36.6 (^tPe CH_2CH_3), 29.4 {^tPe $C(CH_3)_2$ }, 7.9 (^tPe CH_2CH_3). IR (CH_2Cl_2 , cm⁻¹) v_{max} 3173 (w), 2971 (s), 2930 (m), 2880 (m), 1784 (w), 1704 (s), 1559 (w), 1540 (w), 1461 (m), 1394 (m), 1380 (m), 1305 (s), 1271 (s), 1260 (s), 1193 (s), 1150 (s), 1067 (s), 1016 (s). ESI⁺-MS m/z 598.1 (95%, [MNa]⁺), 463.1 (23%), 422.2 (100%), 239.2 (6%). ESI⁺-HRMS calcd. for $C_{17}H_{24}AuF_4N_3NaO_2$ ([MNa]⁺) 598.1362; found 598.1380. Mp 145-147 °C.

2.11 [$Au(N-mal)(I^{t}Pe)$] (12c)

A protocol similar to that used for **11a** gave the title compound as a white solid {from 117 mg, 267 μmol, of [AuCl(I^tPe)] (**12f**)} (128 mg, 256 μmol, 96%). ¹H NMR (400 MHz, CDCl₃) δ 7.05 (s, 2H, imidazole *CH*), 6.54 (s, 2H, mal *CH*), 2.50 (q, J = 7.5 Hz, 4H, ^tPe CH_2CH_3), 1.82 {s, 12H, ^tPe $C(CH_3)_2$ }, 0.67 (t, J = 7.5 Hz, 6H, ^tPe CH_2CH_3). ¹³C NMR (400 MHz, CDCl₃) δ 182.3 (mal C = O), 170.7 (carbene Au-C), 135.9 (mal C = O), 117.3 (imidazole C = O), 61.8 (^tPe quaternary C), 36.3 (^tPe C = O), 29.3 (^tPe C = O), 7.9 (^tPe C = O), 170.7 (carbene O), 170.7 (carbene O), 170.7 (carbene O), 170.7 (carbene O), 170.9 (mal O), 117.3 (imidazole O), 61.8 (^tPe quaternary O), 36.3 (^tPe O), 36.3 (^tPe O), 170.7 (carbene O), 170.7 (carbene O), 170.7 (mal O), 17

Data for photodimer [{Au(*N*-mal)(I^tPe)}₂] (17b): Not isolated {[Au(*N*-mal)(I^tPe)] (12c):[{Au(*N*-mal)(I^tPe)}₂] (17) 76:24}. ¹H NMR (400 MHz, CDCl₃) selected peaks δ 7.05 (s, 2H, imidazole C*H*), 3.33 (s, 2H, imidate CH), 2.50 (q, J = 7.5 Hz, 4H, ^tPe C*H*₂CH₃), 1.82 (s, 12H, ^tPe C(C*H*₃)₂), 0.67 (t, J = 7.5 Hz, 6H, ^tPe CH₂CH₃). ESI⁺-MS m/z 1025.3 (100%, [MNa]⁺), 1003.3 (84%, [MH]⁺), 906.3 (99%, [(ItPe)₂Au₂(mal)]⁺). ESI⁺-HRMS calcd. for C₃₄H₅₂Au₂N₆NaO₄ ([MNa]⁺) 1025.3273; found 1025.3279.

2.12 $[Au(N-ptm)(I^{t}Pe)]$ (12d)

A protocol similar to that used for **11a** gave the title compound as a white solid {from 127 mg, 288 μ mol, of [AuCl(I¹Pe)] (**12f**)} (152 mg, 277 μ mol, 96%). ¹H NMR (400 MHz, CDCl₃) δ 7.69 (dd, J = 5.4 and 3.0 Hz, 2H, ptm aromatic CH), 7.54 (dd, J = 5.4 and 3.0 Hz, 2H, ptm aromatic CH), 7.06 (s, 2H, imidazole CH), 2.56 (q, J = 7.4 Hz, 4H, ¹Pe CH₂CH₃), 1.85 (s, 12H, ¹Pe C(CH₃)₂), 0.68 (t, J = 7.4 Hz, 6H, ¹Pe CH₂CH₃). ¹³C NMR (400 MHz, CDCl₃) δ 178.8 (ptm C = 0), 171.0 (carbene C), 136.4 (ptm O0 aromatic O1, 132.1 (ptm O1, 121.5 (ptm O1, 121.5 (ptm O1, 117.3 (imidazole O1, 61.9 (¹Pe quaternary O2), 36.3 (¹Pe O1, 29.3 (¹Pe O1, 29.3 (¹Pe O1, 29.3 (¬Pe O1, 29.4 (¬Pe O1, 17.4 (¬Pe O1, 18). IR (CH₂Cl₂, cm⁻¹) O1, O2, 36.3 (¬Pe O1, 30.56 (¬Pe O2, 30.56 (¬Pe O3, 30.56 (¬Pe O3, 30.56 (¬Pe O4, 30.57 (¬Pe O5, 36.57 (¬Pe O5, 36.57 (¬Pe O5, 36.57 (¬Pe O6, 36.7 (¬Pe O7), 36.7 (¬Pe O8, 36.7 (¬Pe O9), 36.8 (¬Pe O9),

2.13 $[Au(N-obs)(I^{t}Pe)]$ (12e)

A protocol similar to that used for **11e** gave the title compound as a white solid {from 90.3 mg, 205 μmol, of [AuCl(I¹Pe)] (**12f**)} (113 mg, 193 μmol, 94%). 1 H NMR (400 MHz, CDCl₃) 7.92-7.88 (m, 1H, obs aromatic *CH*), 7.83-7.80 (m, 1H, obs aromatic *CH*), 7.73-7.64 (m, 2H, obs aromatic *CH*), 7.10 (s, 2H, imidazole *CH*), 2.52 (q, J = 7.4 Hz, 4H, 1 Pe $CH_{2}CH_{3}$), 1.85 (s, 12H, CH_{3}), 0.70 (t, J = 7.4 Hz, 6H, 1 Pe $CH_{2}CH_{3}$). 13 C NMR (101 MHz, CDCl₃) δ 167.9 (carbene Au-*C*), 166.0 (obs *C*=O), 141.8 (obs aromatic *C*), 132.9 (obs aromatic *CH*), 132.8 (obs aromatic *CH*), 131.8 (obs aromatic *C*), 124.0 (obs aromatic *CH*), 120.3 (obs aromatic *CH*), 117.6 (imidazole *CH*), 62.0 (1 Pe quaternary *C*), 36.4 (1 Pe $CH_{2}CH_{3}$), 29.4 { 1 Pe $C(CCH_{3})_{2}$ }, 7.9 (1 Pe $CH_{2}CH_{3}$). IR ($CH_{2}CI_{2}$, cm⁻¹) v_{max} 3362 (w), 3172 (w), 3061 (m), 2971 (s), 2931 (m), 2880 (w), 1741 (m), 1689 (s), 1596 (m), 1461 (m), 1380 (m), 1303 (s), 1260 (s), 1249 (s), 1173 (s), 1157 (s), 1123 (m), 1057 (m). ESI⁺-MS m/z 678.1 (4%), 610.1 (90%, [MNa]⁺), 556.2 (3%), 504.1 (11%), 463.1 (100%, [MNa-obs+CI]⁺), 422.2 (3%), 157.1 (5%). ESI⁺-HRMS calcd. for $C_{20}H_{28}AuN_{3}NaO_{3}S$ ([MNa]⁺) 610.1409; found 610.1408. Mp 150 °C (decomp.).

$2.14 [AuBr(I^{t}Pe)] (12g)$

A protocol similar to that used for [AuBr(I^tBu)] (**11g**) gave the title compound as a white solid {from 83.6 mg, 190 µmol of [AuCl(I^tPe)] (**12f**)} (87.9 mg, 180 µmol, 95%). ¹H NMR (400 MHz, CDCl₃) δ 7.05 (s, 2H, imidazole CH), 2.48 (q, J = 7.5 Hz, 4H, ^tPe CH₂CH₃), 1.81 {s, 12H, ^tPe C(CH₃)₂}, 0.65 (t, J = 7.5 Hz, 6H, ^tPe CH₂CH₃). ¹³C NMR (400 MHz, CDCl₃) δ 172.3 (carbene Au-C), 117.2 (imidazole CH), 61.8 (^tPe quaternary C), 36.3 (^tPe CH₂CH₃), 29.3 {^tPe C(CH₃)₂}, 7.9 (^tPe CH₂CH₃). IR (CH₂Cl₂, cm⁻¹) v_{max} 3196 (w), 3172 (w), 3047 (m), 2972 (s), 2930 (m), 2880 (w), 1704 (w), 1566 (w), 1558 (w), 1461 (m), 1406 (w), 1260 (m), 1229 (m), 1271 (s), 1227 (m), 1191 (s), 1064 (w), 1037 (w), 1005 (w). ESI[†]-MS m/z 507.1 (6%, [MNa][†]), 433.2 (15%), 413.3 (2%), 363.1 (19%), 293.0 (100%), 266.0 (2%). ESI[†]-HRMS calcd. for C₁₃H₂₄AuBrN₂Na ([MNa][†]) 507.0681; found. 507.0675. Mp 149-151 °C.

2.15 [Au(*N*-succ)(IMes)] (13a)

A protocol similar to that used for **11a** gave the title compound as a white solid {from 38.2 mg, 71.3 μmol, of [AuCl(IMes)] (**13f**)} (41.6 mg, 69.4 μmol, 97%). ¹H NMR (400 MHz, CDCl₃) δ 7.10 (s, 2H, imidazole *CH*), 7.01 (s, 4H, Mes aromatic *CH*), 2.40 (s, 4H, succ *CH*₂), 2.34 (s, 6H, Mes *para CH*₃), 2.16 (s, 12H, Mes *ortho CH*₃). ¹³C NMR (101 MHz, CDCl₃) δ 188.5 (succ *C*=O), 174.9 (carbene Au-C), 139.4 (Mes aromatic *C*), 134.7 (Mes aromatic *C*), 134.6 (Mes aromatic *C*), 129.4 (Mes aromatic *C*), 122.3 (imidazole *CH*), 31.4 (succ *CH*₂), 21.1 (Mes *para CH*₃), 17.9 (Mes *ortho CH*₃). IR (CH₂Cl₂, cm⁻¹) *v*_{max} 3670 (w), 3141 (m), 3052 (m), 2981 (m), 2359 (w), 1648 (s), 1540 (w), 1488 (m), 1435 (w), 1415 (w), 1351 (m), 1285 (m), 1230 (m). ESI⁺-MS *m/z* 622.2 (15%, [MNa]⁺), 600.2 (100%, [MH]⁺), 528.2 (49%). ESI⁺-HRMS calcd. for C₂₅H₂₉AuN₃O₂ ([MH]⁺) 600.1925; found 600.1924. Mp 170 °C (decomp.).

2.16 [Au(*N*-tfs)(IMes)] (13b)

A protocol similar to that used for **11b** gave the title compound as a white solid {from 101 mg, 188 μ mol, of [AuCl(IMes)] (**13f**)} (109 mg, 163 μ mol, 87%). ¹H NMR (400 MHz, CDCl₃) δ 7.17 (s, 2H, imidazole CH), 7.04 (s, 4H, Mes aromatic CH), 2.36 (s, 6H, Mes μ ara CH₃), 2.16 (s, 12H, Mes μ artho CH₃). ¹⁹F NMR (376 MHz, CDCl₃) δ -127.6 (s, tfs CF₂). ¹³C NMR (101 MHz, CDCl₃) δ 171.9 (carbene Au-C), 170.0 (m, tfs C=O), ¹ 140.0 (Mes aromatic C), 134.6 (Mes aromatic C), 134.2 (Mes aromatic C), 129.6 (Mes aromatic CH), 122.8 (imidazole CH), 107.1 (tt, μ = 267 and 22 Hz, tfs CF₂), 21.1 (Mes μ ara CH₃), 17.8 (Mes μ artho CH₃). IR (CH₂Cl₂, cm⁻¹) ν max 3167 (w), 3141 (w), 3055 (m), 2923 (w), 1784 (w), 1772 (w), 1705 (s), 1670 (w), 1609 (w), 1559 (w), 1540 (w), 1487 (m), 1420 (m), 1381 (w), 1324 (w), 1305 (m), 1235 (w), 1192 (s), 1150 (m), 1067 (m), 1016 (m), ESI⁺-MS μ z 694.1 (100%, [MNa]⁺), 542.2

 $(55\%, [M-tfs+MeCN]^{+})$, 413.3 (3%), 358.1 (5%), 336.1 (5%). ESI⁺-HRMS calcd. for C₂₅H₂₄AuF₄N₃NaO₂ ([MNa]⁺) 694.1362; found 694.1355. Mp 200 °C (decomp.).

2.17 [Au(*N*-mal)(IMes)] (13c)

A protocol similar to that used for **11a** gave the title compound as a white solid {from 151 mg, 282 μmol, of [AuCl(IMes)] (**13f**)} (157 mg, 263 μmol, 93%). 1 H NMR (400 MHz, CDCl₃) δ 7.10 (s, 2H, imidazole C*H*), 7.00 (s, 4H, Mes aromatic C*H*), 6.31 (s, 2H, mal C*H*), 2.33 (s, 6H, Mes *para* C*H*₃), 2.16 (s, 12H, Mes *ortho* C*H*₃). 13 C NMR (101 MHz, CDCl₃) δ 182.1 (mal *C*=O), 175.1 (carbene Au-*C*), 139.5 (Mes aromatic *C*), 135.7 (mal *C*H), 134.7 (Mes aromatic *C*), 134.6 (Mes aromatic *C*), 129.4 (Mes aromatic *C*), 122.3 (imidazole *C*H), 21.1 (Mes *para* CH₃), 18.0 (Mes *ortho* CH₃). IR (CH₂Cl₂, cm⁻¹) v_{max} 3677 (w), 3167 (w), 3141 (w), 3063 (w), 2922 (m), 1730 (m), 1662 (s), 1640 (m), 1608 (m), 1488 (m), 1415 (m), 1380 (m), 1345 (s), 1235 (m), 1177 (m). ESI⁺-MS m/z 598.2 (11%, [MH]⁺), 528.2 (92%), 305.2 (100%, [IMesH]⁺). ESI⁺-HRMS calcd. for C₂₅H₂₇AuN₃O₂ ([MH]⁺) 598.1763; found 598.1737. Mp 200 °C (decomp.).

2.18 [Au(*N*-ptm)(IMes)] (13d)

A protocol similar to that used for **11a** gave the title compound as a white solid {from 71.1 mg, 132 μ mol of [AuCl(IMes)] (**13f**)} (80.3 mg, 124 μ mol, 94%). ¹H NMR (400 MHz, CDCl₃) δ 7.54 (dd, J = 5.4 and 3.0, 2H, ptm aromatic CH), 7.44 (dd, J = 5.4 and 3.0 Hz, 2H, ptm aromatic CH), 7.12 (s, 2H, imidazole CH), 7.02 (s, 4H, Mes aromatic CH), 2.33 (s, 6H, Mes P para P CH₃), 2.20 (s, 12H, Mes P ortho P CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 178.6 (ptm P C=O), 175.2 (carbene Au-P C), 139.5 (Mes aromatic P C), 136.2 (ptm aromatic P C), 134.6 (Mes aromatic P C), 131.8 (ptm aromatic P CH), 129.4 (Mes aromatic P CH), 121.3 (ptm aromatic P CH), 21.1 (Mes P para P CH₃), 18.0 (Mes P ortho P CH₃). IR (CH₂Cl₂, cm⁻¹) P P max 3674 (w), 3458 (w), 3140 (w), 3063 (w), 3045 (m), 2983 (m), 2921 (m), 2324 (w), 1737 (m), 1667 (s), 1639 (m), 1607 (m), 1540 (w), 1488 (m), 1414 (m), 1372 (m), 1351 (m), 1308 (m), 1236 (m), 1176 (m), 1124 (m). ESI⁺-MS P m/z 648.2 (2%, [MH]⁺), 528.2 (50%), 305.2 (100%, [IMesH]⁺), 267.2 (4%), 136.1 (3%). ESI⁺-HRMS calcd. for C₂₉H₂₉AuN₃O₂ ([MH]⁺) 648.1920; found 648.1908. Mp 150 °C (decomp.).

2.19 [Au(*N*-obs)(IMes)] (13e)

A protocol similar to that used for **11e** gave the title compound as a white solid {from 99.9 mg, 186 μ mol, of [AuCl(IMes)] (**13f**)} (115 mg, 168 μ mol, 90%). ¹H NMR (400 MHz, CDCl₃) δ 7.78-7.76 (m, 1H, obs aromatic CH), 7.72-7.70 (m, 1H, obs aromatic CH), 7.62-7.55 (m, 2H, obs aromatic CH), 7.16 (s,

2H, imidazole *CH*), 7.04 (s, 4H, Mes aromatic *CH*), 2.35 (s, 6H, Mes *para CH*₃), 2.19 (s, 12H, Mes *ortho CH*₃). 13 C NMR (101 MHz, CDCl₃) δ 172.9 (carbene Au-*C*), 165.8 (obs *C*=O), 141.6 (obs aromatic *C*), 139.8 (Mes aromatic *C*), 134.6 (Mes aromatic *C*), 134.4 (Mes aromatic *C*), 132.7 (obs aromatic *C*H), 132.6 (obs aromatic *C*H), 131.7 (obs aromatic *C*), 129.5 (Mes aromatic *C*H), 123.9 (obs aromatic *C*H), 122.5 (imidazole *C*H), 120.1 (obs aromatic *C*H), 21.2 (Mes *para C*H₃), 17.9 (Mes *ortho C*H₃). IR (CH₂Cl₂, cm⁻¹) v_{max} 3167 (w), 3141 (w), 3054 (m), 2982 (w), 2952 (w), 2922 (m), 2861 (w), 1689 (s), 1608 (w), 1599 (w), 1559 (w), 1540 (w), 1487 (m), 1459 (w), 1419 (m), 1380 (m), 1337 (w), 1303 (s), 1248 (m), 1173 (s), 1157 (s), 1123 (w). ESI⁺-MS m/z 706.1 (13%, [MNa]⁺), 542.2 (100%, [Mobs+MeCN]⁺), 413.3 (2%), 235.1 (2%). ESI⁺-HRMS calcd. for C₂₈H₂₈AuN₃NaO₃S ([MNa]⁺) 706.1409; found 706.1415. Mp 160 °C (decomp.).

2.20 $[AuBr_2(N-succ)(I^tBu)]$ (18a)

[Au(*N*-succ)(I^tBu)] (11a) (28.5 mg, 59.9 μmol, 1 equiv.) was dissolved in dichloromethane (1 ml), bromine (10.5 mg, 65.9 μmol, 1.1 equiv.) was added and the brown solution stirred for 1 hour at room temperature. The solution was reduced *in vacuo* to <0.5 ml and pentane (5 ml) added producing a yellow precipitate. This was separated by filtration, washed (pentane/diethyl ether) and dried *in vacuo* to give the title compound as a yellow powder (32.2 mg, 50.6 μmol, 84%). ¹H NMR (400 MHz, CDCl₃) δ 7.41 (s, 2H, imidazole *CH*), 2.72 (s, 4H, succ *CH*₂), 1.96 {s, 18H, ^tBu $C(CH_3)_3$ }. ¹³C NMR (400 MHz, CDCl₃) δ 183.8 (succ *C*=O), 131.9 (carbene Au-*C*), 122.1 (imidazole *CH*), 62.4 (^tBu $C(CH_3)_3$), 32.1 (^tBu $C(CH_3)_3$), 31.4 (succ *CH*₂). IR (CH₂Cl₂, cm⁻¹) v_{max} 3168 (w), 3063 (w), 2988 (m), 2360 (w), 1663 (s), 1576.1 (m), 1480 (w), 1415 (w), 1375 (m), 1352 (m), 1284 (w), 1230 (m), 1196 (w), 1182 (m), 1156 (w). ESI⁺-MS m/z 636.0 (81%, [MH]⁺), 418.2 (66%), 259.1 (15%, [I^tBuBr]⁺), 181.2 (100%, [I^tBuH]⁺). ESI⁺-HRMS calcd. for C₁₅H₂₃AuBr₂N₃O₂ ([MH]⁺) 633.9949; found 633.9974. Mp 160 °C (decomp.).

2.21 $[AuBr_2(N-dbs)(I^tBu)]$ (18b)

[Au(*N*-mal)(I^tBu)] (**11c**) (30.1 mg, 63.6 μmol, 1 equiv.) was dissolved in dichloromethane (1 ml), bromine (20.4 mg, 128 μmol, 2 equiv.) was added and the yellow solution stirred for 1 hour at room temperature. The solution was reduced *in vacuo* to <0.5 ml and hexane (5 ml) added producing a yellow precipitate. This was separated by filtration, washed (pentane, diethyl ether) and dried *in vacuo* to give the title compound as a yellow powder (37.5 mg, 59.2 μmol, 93%). ¹H NMR (400 MHz, CDCl₃) δ 7.47 (s, 2H, imidazole *CH*), 4.82 (s, 2H, dbs *CH*), 1.99 {s, 18H, ^tBu $C(CH_3)_3$ }. ¹³C NMR (400 MHz, CDCl₃) δ 175.7 (dbs *C*=O), 128.1 (carbene Au-*C*), 122.4 (imidazole *CH*), 62.6 (^tBu $C(CH_3)_3$), 46.6 (dbs *CH*), 32.1 {^tBu $C(CH_3)_3$ }. IR (CH₂Cl₂, cm⁻¹) v_{max} 3054 (m), 2986 (m), 2360 (m), 2341 (m), 1733 (m), 1690 (s), 1653

(m), 1636 (m), 1559 (m), 1540 (m), 1521 (m), 1507 (m), 1497 (m), 1473 (m), 1457 (m), 1437 (m), 1420 (m), 1376 (m), 1338 (m), 1271 (s), 1230 (m), 1179 (m). ESI $^+$ -MS m/z 815.8 (100%, [MNa] $^+$), 733.9 (3%, [MNa–HBr] $^+$), 664.9 (4%), 596.9 (4%), 528.9 (4%). ESI $^+$ -HRMS calcd. for $C_{15}H_{22}AuBr_4N_3NaO_2$ ([MNa] $^+$) 815.7963; found 815.7958. Mp 160 °C (decomp.).

2.22 $[AuBr_2(N-tfs)(I^tBu)]$ (18c)

A protocol similar to that used for **18a** gave the title compound as a yellow powder {from 57.0 mg, 104 μmol, of [Au(N-tfs)(I^tBu)] (**11b**)} (67.2 mg, 95.0 μmol, 91%). 1 H NMR (400 MHz, CDCl₃) δ 7.51 (s, 2H, imidazole CH), 1.98 {s, 18H, t Bu C(C H_3)₃}. 19 F NMR (376 MHz, CDCl₃) δ -127.1 (s, tfs C F_2). 13 C NMR (100 MHz, CDCl₃) δ 167.1 (m, tfs C=O), 1 124.9 (carbene Au-C), 122.8 (imidazole CH), 106.8 (tt, J = 269 and 23 Hz, tfs CF₂), 62.8 { t Bu C(CH₃)₃}, 32.0 { t Bu C(CH₃)₃}. IR (CH₂Cl₂, cm⁻¹) v_{max} 3491 (w), 3200 (w), 3168 (w), 3056 (w), 2987 (m), 1789 (w), 1718 (s), 1584 (w), 1479 (m), 1418 (m), 1386 (m), 1376 (m), 1322 (m), 1305 (s), 1197 (s), 1156 (s), 1065 (m), 1017 (m). ESI⁺-MS m/z 797.9 (3%), 729.9 (100%, [MNa]⁺), 498.9 (2%), 259.1 (6%, [I^tBu+HBr]⁺), 227.0 (3%), 191.1 (1%), 107.2 (2%). ESI⁺-HRMS calcd. for C₁₅H₂₀AuBr₂F₄N₃NaO₂ ([MNa]⁺) 729.9396; found 729.9390. Mp 160°C (decomp.).

2.23 $[AuBr_2(N-mal)(I^tBu)]$ (18d)

[Au(N-mal)(I¹Bu)] (11c) (51.2 mg, 108 µmol, 1 equiv.) was dissolved in dichloromethane (1 ml), bromine (17.3 mg, 108 µmol, 1 equiv.) was added and the brown solution stirred for 1 hour at -78°C. The solution was reduced under vacuum to <0.5 ml and pentane (5 ml) added producing a yellow precipitate. This was separated by filtration, washed (pentane, diethyl ether) and dried *in vacuo* to give the title compound as a yellow powder (61.3 mg, 96.8 µmol, 90%). ¹H NMR (400 MHz, CDCl₃) δ 7.44 (s, 2H, imidazole CH), 6.64 (s, 2H, mal CH), 2.01 {s, 18H, t Bu C(CH_3)₃}. ¹³C NMR (100 MHz, CDCl₃) δ 177.3 (mal C=O), 136.8 (mal CH), 131.2 (carbene Au-C), 122.2 (imidazole CH), 62.4 { t Bu C(CH₃)₃}, 32.1 { t Bu C(CH₃)₃}. IR (CH₂Cl₂, cm⁻¹) v_{max} 3200 (w), 3169 (w), 3055 (m), 2985 (m), 1733 (m), 1676 (s), 1653 (w), 1589 (w), 1540 (w), 1506 (w), 1417 (m), 1376 (m), 1346 (s), 1321 (w), 1271 (s), 1233 (m), 1181 (s), 1155 (m), 1063 (w). ESI⁺-MS m/z 656.0 (100%, [MNa]⁺), 498.9 (4%, [MNa-2Br]⁺), 430.9 (4%), 289.2 (10%). ESI⁺-HRMS calcd. for C_{15} H₂₂AuBr₂N₃NaO₂ ([MNa]⁺) 655.9617; found 655.9649. Mp 190 °C (decomp.).

2.24 $[AuBr_2(N-ptm)(I^tBu)]$ (18e)

A protocol similar to that used for **11a** gave the title compound as a yellow powder {from 99.1 mg, 189 μ mol, of [Au(N-ptm)(I^tBu)] (**11d**)} (115 mg, 168 μ mol, 89%). ¹H NMR (400 MHz, CDCl₃) δ 7.71 (dd, J = 5.4 and 3.0 Hz, 2H, ptm *meta* aromatic CH), 7.57 (dd, J = 5.4 and 3.0 Hz, 2H, ptm *para* aromatic CH),

7.45 (s, 2H, imidazole *CH*), 2.04 {s, 18H, ^tBu C(CH_3)₃}. ¹³C NMR (101 MHz, CDCl₃) δ 174.4 (ptm *C*=O), 136.4 (ptm aromatic *C*), 132.2 (ptm aromatic *C*H), 131.5 (carbene Au-*C*), 122.1 (imidazole *C*H), 121.9 (ptm aromatic *C*H), 62.5 {^tBu $C(CH_3)_3$ }, 32.2 {^tBu $C(CH_3)_3$ }. IR (CH_2Cl_2 , cm⁻¹) v_{max} 3053 (m), 2987 (m), 2359 (w), 1682 (s), 1646 (m), 1609 (w), 1540 (w), 1465 (m), 1417 (m), 1374 (m), 1352 (m), 1312 (s), 1178 (m), 1157 (w), 1128 (m). ESI⁺-MS m/z 684.0 (51%, [MH]⁺), 418.2 (51%), 338.3 (18%), 259.1 (36%, [I^tBuBr]⁺), 181.2 (100%, [ItBuH]⁺). ESI⁺-HRMS calcd. for $C_{19}H_{25}AuBr_2N_3O_2$ ([MH]⁺) 681.9974; found 681.9988. Mp 210 °C (decomp.).

$2.25 [AuBr_2(N-obs)(I^tBu)] (18f)$

A protocol similar to that used for **18a** gave the title compound as a yellow powder {from 38.4 mg, 68.7 μmol, of [Au(*N*-obs)(I^tBu)] (**11e**)} (45.4 mg, 63.1 μmol, 92%). ¹H NMR (400 MHz, CDCl₃) δ 7.93-7.84 (m, 2H, aromatic *CH*), 7.72-7.66 (m, 2H, aromatic *CH*), 7.50 (s, 2H, imidazole *CH*), 2.03 {s, 18H, ^tBu C(*CH*₃)₃}. ¹³C NMR (100 MHz, CDCl₃) δ 164.0 (obs *C*=O), 142.3 (obs aromatic *C*), 133.0 (obs aromatic *CH*), 131.3 (obs aromatic *CH*), 125.6 (carbene Au-*C*), 124.1 (obs aromatic *CH*), 122.7 (imidazole *CH*), 120.5 (obs aromatic *CH*), 62.7 {^tBu *C*(*CH*₃)₃}, 32.0 {^tBu *C*(*CH*₃)₃}). IR (*CH*₂Cl₂, cm⁻¹) *v*_{max} 3676 (w), 3062 (w), 2986 (m), 2929 (m), 1734 (w), 1694 (s), 1653 (w), 1597 (w), 1559 (w), 1460 (m), 1417 (m), 1376 (m), 1336 (w), 1315 (s), 1287 (m), 1247 (m), 1192 (w), 1176 (s), 1158 (m), 1124 (w), 1014 (w), 979 (m), 971 (m). ESI[†]-MS *m/z* 741.9 (100%, [MNa][†]), 698.0 (2%), 640.9 (1%), 582.1 (2%), 481.0 (7%), 435.1 (6%), 336.1 (1%), 259.1 (15%), 215.1 (2%), 181.2 (4%), 147.0 (2%). ESI[†]-HRMS calcd. for C₁₈H₂₄AuBr₂N₃NaO₃S ([MNa][†]) 741.9448; found 741.9442. Mp 150 °C (decomp.).

$2.26 [AuBr_3(I^tBu)] (18g)$

Prepared by a protocol reported by de Frémont *et al.*² [AuBr(I^tBu)] (**11g**) (40.7 mg, 89.1 μmol, 1 equiv.) was dissolved in dichloromethane (2 ml) and bromine (0.80 ml, 98 μmol, 1.1 equiv.) was added. The orange solution was stirred at room temperature for 1 hour. The volume was reduced *in vacuo* to <0.5 ml and hexane added to give an orange precipitate. This was separated by filtration, washed (hexane) and dried *in vacuo* to give the title compound as an orange powder (53.1 mg, 86.1 μmol, 97%). ¹H NMR (400 MHz, CDCl₃) δ 7.45 (s, 2H, imidazole C*H*), 1.94 (s, 18H, ^tBu C*H*₃). ¹³C NMR (100 MHz, CDCl₃) δ 134.8 (carbene Au-*C*), 122.2 (imidazole C*H*), 62.4 (^tBu quaternary *C*), 32.0 (^tBu C*H*₃). ESI[†]-MS m/z 656.8 (61%, [MK][†]), 640.9 (100%, [MNa][†]), 633.9 (30%), 582.8 (12%), 526.7 (8%), 481.0 (7%, [MNa-2Br][†]), 429.4 (16%), 413.3 (58%), 369.3 (36%), 349.1 (24%), 293.0 (70%), 259.1 (77%). ESI[†]-HRMS calcd. for C₁₁H₂₀N₂AuBr₃Na 640.8694 ([MNa][†]); found 640.8677.

2.27 [AuBr₂(N-succ)(I^tPe)] (19a)

A protocol similar to that used for **18a** gave the title compound as a yellow powder {from 98.8 mg, 196 μ mol, of [Au(N-succ)(I^tPe)] (**12a**)} (127 mg, 192 μ mol, 98%). ¹H NMR (400 MHz, CDCl₃) δ 7.36 (s, 2H, imidazole CH), 2.74 (s, 4H, succ CH_2), 2.04 (s, 12H, ^tPe $C(CH_3)_2$), 2.03 (q, J = 7.5 Hz, 4H, ^tPe CH_2CH_3), 0.84 (t, J = 7.5 Hz, 6H, ^tPe CH_2CH_3). ¹³C NMR (101 MHz, CDCl₃) δ 183.9 (succ C=O), 132.6 (carbene Au-C), 122.1 (imidazole CH), 65.4 (^tPe quaternary C), 36.8 (^tPe CH_2CH_3), 31.4 (succ CH_2), 29.8 {^tPe $C(CH_3)_2$ }, 8.5 (^tPe CH_2CH_3). IR (solid, cm⁻¹) v_{max} 2967 (w), 1665 (s), 1461 (w), 1414 (w), 1224 (s), 1003 (s), 798 (s), 683 (m). IR (CH_2Cl_2 , cm⁻¹) v_{max} 3686 (w), 3052 (m), 2979 (m), 2940 (w), 2882 (w), 1663 (s), 1540 (w), 1465 (m), 1434 (w), 1414 (w), 1387 (m), 1352 (m), 1284 (m), 1230 (m), 1176 (w). ESI⁺-MS m/z 664.0 (100%, [MH]⁺), 593.9 (72%), 523.9 (86%), 472.9 (21%), 433.2 (34%), 414.3 (93%), 391.3 (99%), 289.1 (58%), 217.0 (42%), 149.0 (58%), 127.3 (23%). ESI⁺-HRMS calcd. for $C_{17}H_{29}AuBr_2N_3O_2$ ([MH]⁺) 662.0287; found 662.0313. Mp 190 °C (decomp.).

2.28 [AuBr₂(N-dbs)(I^{t} Pe)] (19b)

A protocol similar to that used for **18b** gave the title compound as a yellow powder {from 31.4 mg, 62.7 μ mol, of [Au(N-mal)(I^tPe)] (**12c**)} (36.2 mg, 54.8 μ mol, 87%). ¹H NMR (400 MHz, CDCl₃) δ 7.39 (s, 2H, imidazole CH), 4.81 (s, 2H, dbs CH), 2.03 {m, 16H, ^tPe C H_2 CH₃ and ^tPe C(C H_3)₂}, 0.85 (t, J = 7.4 Hz, 6H, tPe CH₂CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 175.7 (dbs C=O), 128.7 (carbene Au-C), 122.4 (imidazole CH), 65.6 (^tPe quaternary C), 46.6 (dbs C-H), 36.8 (^tPe CH₂CH₃), 29.7 {^tPe C(CH₃)₂}, 8.5 (^tPe CH₂CH₃). IR (CH₂Cl₂, cm⁻¹) v_{max} 3421 (w), 3200 (w), 2976 (w), 2976 (m), 2930 (w), 2360 (m), 2341 (m), 1741 (m), 1690 (s), 1465 (m), 1419 (m), 1387 (m), 1337 (s), 1269 (s), 1227 (m), 1198 (w), 1174 (w). ESI⁺-MS m/z 843.8 (100%, [MNa]⁺). ESI⁺-HRMS calcd. for C₁₇H₂₆AuBr₄N₃NaO₂ ([MNa]⁺) 843.8277; found 843.8288. Mp 170 °C (decomp.).

2.29 [AuBr₂(N-tfs)(I^tPe)] (19c)

A protocol similar to that used for **18a** gave the title compound as a yellow powder {from 50.5 mg, 87.8 μ mol, of [Au(*N*-tfs)(I^tPe)] (**12b**)} (60.0 mg, 81.6 μ mol, 93%). ¹H NMR (400 MHz, CDCl₃) δ 7.43 (s, 2H, imidazole C*H*), 2.05 {s, 12H, ^tPe C(C*H*₃)₂}, 2.04 (q, *J* = 7.5 Hz, 4H, ^tPe C*H*₂CH₃), 0.86 (t, *J* = 7.5 Hz, 6H, ^tPe CH₂CH₃). ¹⁹F NMR (376 MHz, CDCl₃) δ -127.1 (s, C*F*₂). ¹³C NMR (101 MHz, CDCl₃) δ 167.0 (m, *C*=O), ⁷ 126.0 (carbene Au-*C*), 122.8 (imidazole *C*H), 107.0 (tt, *J* = 269 and 23 Hz, C*F*₂), 65.8 (^tPe quaternary *C*), 36.8 (^tPe *C*H₂CH₃), 29.7 (^tPe C(*C*H₃)₂), 8.5 (^tPe *C*H₂CH₃). IR (CH₂Cl₂, cm⁻¹) ν_{max} 3490 (w), 3200 (w), 3166 (w), 2979 (m), 2941 (w), 2884 (w), 1819 (w), 1789 (w), 1720 (m), 1716 (s), 1586 (w), 1480 (w), 1465 (w), 1417 (w), 1387 (m), 1322 (m), 1305 (m), 1195 (s), 1156 (m), 1065 (m), 1017 (m).

 $ESI^{+}-MS \ m/z \ 799.0 \ (6\%, [MNa+MeCN]^{+}), 758.0 \ (100\%, [MNa]^{+}), 598.1 \ (3\%), 463.1 \ (4\%). ESI^{+}-HRMS$ calcd. for $C_{17}H_{24}AuBr_{2}F_{4}N_{3}NaO_{2} \ ([MNa]^{+}) \ 757.9714$; found 757.9703. Mp 150 °C (decomp.).

2.30 [AuBr₂(N-mal)(I^tPe)] (19d)

A protocol similar to that used for **18d** gave the title compound as a yellow powder {from 30.1 mg, 60.1 μmol, of [Au(N-mal)(I^tPe)] (**12c**)} (34.7 mg, 52.5 μmol, 87%). ¹H NMR (400 MHz, CDCl₃) δ 7.38 (s, 2H, imidazole CH), 6.64 (s, 2H, mal CH), 2.07 {s, 12H, ^tPe C(CH₃)₂}, 2.03 (q, J = 7.5 Hz, 4H, ^tPe CH₂CH₃), 0.86 (t, J = 7.5 Hz, 6H, ^tPe CH₂CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 177.3 (mal C=O), 136.8 (mal CH), 132.0 (carbene Au-C), 122.2 (imidazole CH), 65.4 (^tPe quaternary C), 36.9 (^tPe CH₂CH₃), 29.8 {^tPe C(CH₃)₂}, 8.6 (^tPe CH₂CH₃). IR (CH₂Cl₂, cm⁻¹) v_{max} 3054 (m), 2979 (m), 2940 (w), 2883 (w), 2360 (m), 2342 (m), 1734 (m), 1676 (s), 1437 (m), 1419 (m), 1348 (s), 1269 (s), 1180 (m). ESI⁺-MS m/z 684.0 (100%, [MNa]⁺), 649.2 (33%), 619.0 (9%), 524.2 (12%). ESI⁺-HRMS calcd. for C₁₇H₂₆AuBr₂N₃NaO₂ 683.9935; found 683.9901. Mp 160 °C (decomp.).

2.31 $[AuBr_2(N-ptm)(I^tPe)]$ (19e)

A protocol similar to that used for **18a** gave the title compound as a yellow powder $\{98.5 \text{ mg}, 179 \text{ }\mu\text{mol}, \text{ of } [\text{Au}(N-\text{ptm})(\text{I}^{\text{t}}\text{Pe})] \text{ } (12\text{d}) \} \text{ } (123 \text{ mg}, 173 \text{ }\mu\text{mol}, 97\%). }^{1}\text{H NMR } (400 \text{ MHz}, \text{CDCl}_3) \text{ } \delta \text{ } 7.70 \text{ } (\text{dd}, J = 5.4 \text{ and } 3.0 \text{ Hz}, 2\text{H}, \text{ ptm aromatic } CH), 7.39 \text{ } (\text{s}, 2\text{H}, \text{ imidazole } CH), 2.10 \text{ } (\text{s}, 12\text{H}, ^{\text{t}}\text{Pe } \text{C}(CH_3)_2), 2.05 \text{ } (\text{q}, J = 7.4 \text{ Hz}, 4\text{H}, ^{\text{t}}\text{Pe } \text{CH}_2\text{CH}_3), 0.86 \text{ } (\text{t}, J = 7.4 \text{ Hz}, 6\text{H}, ^{\text{t}}\text{Pe } \text{CH}_2\text{CH}_3). }^{13}\text{C NMR } \text{ } (101 \text{ MHz}, \text{CDCl}_3) \text{ } \delta \text{ } 174.3 \text{ } (\text{ptm } C=\text{O}), 136.2 \text{ } (\text{ptm } \textit{ortho} \text{ aromatic } C), 132.4 \text{ } (\text{carbene Au-}C), 132.3 \text{ } (\text{ptm } \textit{meta} \text{ aromatic } C), 122.3 \text{ } (\text{ptm } \textit{para} \text{ aromatic } C), 121.8 \text{ } (\text{imidazole } C\text{H}), 65.3 \text{ } (^{\text{t}}\text{Pe} \text{ quaternary } C), 36.8 \text{ } (^{\text{t}}\text{Pe } \text{CH}_2\text{CH}_3), 29.8 \text{ } (^{\text{t}}\text{Pe } \text{C}(\text{CH}_3)_2), 8.5 \text{ } (^{\text{t}}\text{Pe } \text{CH}_2\text{CH}_3). \text{ } \text{IR } \text{ } (\text{CH}_2\text{Cl}_2, \text{ cm}^{-1}) \text{ } \textit{v}_{\textit{max}} \text{ } 3199 \text{ } (\text{w}), 3057 \text{ } (\text{w}), 2940 \text{ } (\text{w}), 2882 \text{ } (\text{w}), 1742 \text{ } (\text{w}), 1682 \text{ } (\text{s}), 1646 \text{ } (\text{m}), 1609 \text{ } (\text{w}), 1540 \text{ } (\text{w}), 1465 \text{ } (\text{m}), 1416 \text{ } (\text{m}), 1373 \text{ } (\text{m}), 1352 \text{ } (\text{m}), 1311 \text{ } (\text{s}), 1284 \text{ } (\text{m}), 1214 \text{ } (\text{w}), 1175 \text{ } (\text{m}), 1128 \text{ } (\text{m}). \text{ } \text{ESI}^{+}\text{-MS} \text{ } \textit{m/z} \text{ } 712.0 \text{ } (100\%, [\text{MH}]^{+}), 642.0 \text{ } (41\%, [\text{MH}^{-\text{t}}\text{Pe}]^{+}), 571.9 \text{ } (35\%, [\text{MH}_2\text{-}^{\text{2}}\text{Pe}]^{+}), 472.9 \text{ } (6\%), 391.3 \text{ } (68\%), 363.1 \text{ } (3\%), 289.1 \text{ } (16\%, [\text{I}^{\text{t}}\text{PeBr}]^{+}), 272.7 \text{ } (18\%), 217.0 \text{ } (14\%, [\text{I}^{\text{t}}\text{PeBr}\text{H}^{-\text{t}}\text{Pe}]^{+}), 149.0 \text{ } (24\%), 127.3 \text{ } (5\%).$ ESI $^{+}$ -HRMS calcd. for C₂₁H₂₉AuBr₂N₃O₂ ([\text{MH}]^{+}) 710.0287; found 710.0309. \text{ Mp } 220 \text{ } \text{°C} \text{ } \text{ } \text{decomp}.).

2.32 $[AuBr_2(N-obs)(I^tPe)]$ (19f)

A protocol similar to that used for **18a** gave the title compound as a yellow powder {from 40.6 mg, 69.2 μ mol, of [Au(N-obs)(I^tPe)] (**12e**)} (48.6 mg, 65.1 μ mol, 94%). ¹H NMR (400 MHz, CDCl₃) δ 7.97-7.93 (m, 1H, obs aromatic CH), 7.90-7.87 (m, 1H, obs aromatic CH), 7.72-7.66 (m, 2H, obs aromatic CH), 7.43 (s, 2H, imidazole CH), 2.12 {s, 12H, ^tPe C(CH₃)₂}, 2.05 (q, J = 7.4 Hz, 4H, ^tPe CH₂CH₃), 0.88 (t, J =

7.4 Hz, 6H, ^tPe CH₂CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 164.0 (obs *C*=O), 142.3 (obs aromatic *C*), 133.0 (obs aromatic 2*C*H), 131.3 (obs aromatic *C*), 126.6 (carbene Au-*C*), 124.1 (obs aromatic *C*H), 122.7 (imidazole *C*H), 120.4 (obs aromatic *C*H), 65.8 (^tPe quaternary *C*), 36.9 (^tPe *C*H₂CH₃), 29.7 {s, ^tPe C(*C*H₃)₂}, 8.6 (s, ^tPe CH₂CH₃). IR (CH₂Cl₂, cm⁻¹) v_{max} 3675 (w), 3199 (w), 3063 (w), 2979 (m), 2940 (m), 2883 (m), 1694 (s), 1653 (w), 1596 (m), 1506 (w), 1461 (m), 1417 (m), 1388 (m), 1337 (w), 1315 (s), 1248 (s), 1192 (w), 1176 (s), 1160 (m), 1124 (w), 1059 (w). ESI⁺-MS m/z 838.0 (4%), 770.0 (100%, [MNa]⁺), 633.0 (12%), 446.2 (11%). ESI⁺-HRMS calcd. for C₂₀H₂₈AuBr₂N₃NaO₃S ([MNa]⁺) 769.9761; found 769.9764. Mp 180 °C (decomp.).

$2.33 [AuBr_3(I^tPe)] (19g)$

A protocol similar to that used for **18g** gave the title compound as an orange solid {from 40.7 mg, 89.1 μ mol, of [AuBr(I^tPe)] (**12g**)} (53.1 mg, 86.1 μ mol, 97%). ¹H NMR (400 MHz, CDCl₃) δ 7.39 (s, 2H, imidazole CH), 2.02 (q, J = 7.5 Hz, 4H, ^tPe CH₂CH₃), 2.01 {s, 12H, ^tPe C(CH₃)₂}, 0.86 (t, J = 7.5 Hz, 6H, ^tPe CH₂CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 135.6 (carbene Au-C), 122.2 (imidazole CH), 65.5 (^tPe quaternary C), 36.7 (^tPe CH₂CH₃), 29.6 {^tPe C(CH₃)₂}, 8.6 (^tPe CH₂CH₃). IR (CH₂Cl₂, cm⁻¹) v_{max} 3200 (m), 3165 (m), 3050 (m), 2979 (s), 2941 (m), 2883 (m), 1585 (w), 1465 (m), 1413 (m), 1382 (m), 1281 (w), 1260 (s), 1199 (m), 1175 (s), 1161 (m), 1067 (w), 1033 (w), 1006 (w). ESI[†]-MS m/z 666.9 (100%, [MNa][†]), 507.1 (54%), 463.1 (8%), 289 (37%). ESI[†]-HRMS calcd. for C_{13} H₂₄AuBr₃N₂Na ([MNa][†]) 666.9027; found 666.9066. Mp 170 °C (decomp.).

$2.34 \left[\text{AuBr}_2(N\text{-succ})(\text{IMes}) \right] (20a)$

A protocol similar to that used for **18a** gave the title compound as a yellow powder {57.9 mg, 96.7 μmol, of [Au(*N*-succ)(IMes)] (**13a**)} (63.3 mg, 83.4 μmol, 86%). ¹H NMR (400 MHz, CDCl₃) δ 7.26 (s, 2H, imidazole C*H*), 7.06 (s, 4H, Mes aromatic C*H*), 2.52 (s, 4H, succ C*H*₂), 2.37 (s, 6H, Mes *para* C*H*₃), 2.33 (s, 12H, Mes *ortho* C*H*₃). ¹³C NMR (100 MHz, CDCl₃) δ 183.1 (succ *C*=O), 142.2 (carbene Au-*C*), 140.6 (Mes aromatic *C*), 135.0 (Mes aromatic *C*), 133.0 (Mes aromatic *C*), 129.9 (Mes aromatic *C*H), 125.5 (imidazole *C*H), 31.3 (succ *C*H₂), 21.2 {Mes *para* C(*C*H₃)}, 19.5 {Mes *ortho* C(*C*H₃)}. IR (CH₂Cl₂, cm⁻¹) v_{max} 3677 (w), 3144 (w), 3055 (m), 2979 (w), 2924 (w), 2363 (w), 1723 (w), 1665 (s), 1608 (w), 1540 (w), 1482 (m), 1434 (m), 1381 (w), 1351 (m), 1281 (m), 1232 (m), 1168 (w). ESI⁺-MS *m/z* 782.0 (10%, [MNa]⁺), 760.0 (100%, [MH]⁺), 542.2 (5%). ESI⁺-HRMS calcd. for C₂₅H₂₉AuBr₂N₃O₂ ([MH]⁺) 758.0287; found 758.0282. Mp 180 °C (decomp.).

$2.35 \left[\text{AuBr}_2(N\text{-mal})(\text{IMes}) \right] (20b)$

A protocol similar to that used for **18d** gave the title compound as a yellow powder {105 mg, 176 μmol, of [Au(*N*-mal)(IMes)] (**13c**)} (129 mg, 170 μmol, 96%). ¹H NMR (400 MHz, CDCl₃) δ 7.27 (s, 2H, *CH* imidazole), 7.07 (s, 4H, Mes aromatic *CH*), 6.39 (s, 2H, mal *CH*), 2.33 (m, 18 H, Mes *CH*₃). ¹³C NMR (101 MHz, CDCl₃) δ 176.6 (mal *C*=O), 141.4 (carbene Au-*C*), 140.7 (Mes aromatic *C*), 136.7 (mal *C*H), 135.0 (Mes aromatic *C*), 133.0 (Mes aromatic *C*), 129.9 (Mes aromatic *C*H), 125.6 (imidazole *C*H), 21.2 (Mes *para* CCH₃), 19.5 (Mes *ortho* CCH₃). IR (CH₂Cl₂, cm⁻¹) v_{max} 3686 (w), 3143 (w), 2984 (w), 2352 (w), 1677 (s), 1608 (m), 1540 w), 1484 (m), 1432 (w), 1380 (w), 1349 (m), 1284 (w), 1229 (m), 1181 (m), 1128 (w). ESI⁺-MS *m/z* 758.0 (1%, [MH]⁺), 620.2 (12%, [MNa-2Br]⁺), 598.2 (88%, [MH-2Br]⁺), 550.2 (4%), 529.2 (64 %), 385.1 (31%, [IMesBr]⁺), 335.2 (2%), 305.2 (100%, [IMesH]⁺), 267.2 (2%). ESI⁺-HRMS calcd. for C₂₅H₂₇AuBr₂N₃O₂ ([MH]⁺) 758.0115; found 758.0185. Mp 190 °C (decomp.).

$2.36 \left[\text{AuBr}_2(N-\text{ptm})(\text{IMes}) \right] (20c)$

A protocol similar to that used for **18a** gave the title compound as a yellow powder $\{40.3 \text{ mg}, 62.3 \text{ } \mu\text{mol}, \text{ of } [\text{Au}(N-\text{ptm})(\text{IMes})] \text{ } (13\text{d}) \}$ (48.0 mg, 59.4 $\mu\text{mol}, 95\%$). ¹H NMR (400 MHz, CDCl₃) δ 7.56 (dd, J=5.4 and 3.0 Hz, 2H, ptm aromatic CH), 7.44 (dd, J=5.4 and 3.0 Hz, 2H, ptm aromatic CH), 7.29 (s, 2H, imidazole CH), 7.09 (s, 4H, Mes aromatic CH), 2.38 (s, 6H, Mes para CCH₃), 2.34 (s, 12H, Mes ortho CCH₃). ¹³C NMR (400 MHz, CDCl₃) δ 173.7 (ptm C=O), 142.2 (carbene Au-C), 140.6 (Mes aromatic C), 136.3 (ptm ortho aromatic C), 135.0 (Mes aromatic C), 133.1 (Mes aromatic C), 132.0 (ptm meta aromatic CH), 129.9 (Mes aromatic CH), 125.6 (imidazole CH), 121.7 (ptm para aromatic CH), 21.2 {Mes para C(CH₃)}, 19.5 {Mes ortho C(CH₃)}. IR (CH₂Cl₂, cm⁻¹) v_{max} 3686 (w), 3421 (w), 3170 (w), 3143 (w), 2925 (w), 2360 (w), 1777 (w), 1741 (m), 1683 (s), 1646 (m), 1609 (m), 1540 (w), 1484 (m), 1418 (w), 1372 (m), 1351 (m), 1310 (m), 1230 (m), 1172 (m), 1129 (m). ESI⁺-MS m/z 808.0 (100%, [MH]⁺), 728.1 (2%, [M-Br]⁺), 648.2 (48%, [MH-2Br]⁺), 622.1 (4%), 542.2 (84%). ESI⁺-HRMS calcd. for C₂₉H₂₉AuBr₂N₃O₂ ([MH]⁺) 808.0268; found 808.0283. Mp 125-127 °C.

2.37 [Au(N^{15} -succ)(I^tPe)] (^{15}N -12a)

¹⁵N-Succinimide (15.8 mg, 15.8 μmol, 1.1 equiv.), silver(I) oxide (20.0 mg, 86.2 μmol, 0.6 equiv.) and [AuCl(I^tPe)] (**12f**) (63.2 mg, 144 μmol, 1 equiv.) were mixed in dichloromethane (2 ml) in the absence of light for 18 hours. The suspension was filtered through CeliteTM, reduced to <0.5 ml and pentane added, resulting in a white precipitate. This was washed (cold pentane and diethyl ether) and dried *in vacuo* to give the title compound as a white powder (65.2 mg, 130 μmol, 90%). ¹H NMR (400 MHz, CDCl₃) δ 7.04 (s, 2H, imidazole C*H*), 2.61 (s, 4H, succ C*H*₂), 2.48 (q, J = 7.5 Hz, 4H, ^tPe C*H*₂), 1.81 {s, 12H, ^tPe

 $C(CH_3)_2$, 0.65 (t, J = 7.5 Hz, 6H, ^tPe CH_2CH_3). ¹³C NMR (100 MHz, $CDCl_3$) δ 188.7 (d, J = 8 Hz, succ C=O), 170.8 (d, J = 15 Hz, carbene Au-C), 117.3 (imidazole CH), 61.8 (^tPe quaternary C), 36.3 (^tPe CH_2CH_3), 31.6 (d, J = 4 Hz, succ CH_2), 29.3 ($^{t}Pe C(CH_3)_2$), 7.9 ($^{t}Pe CH_2CH_3$). $^{15}N NMR$ (50 MHz, CD_2Cl_2) δ 209.4 (s). IR (solid, cm⁻¹) v_{max} 2964 (m), 2933 (w), 2533 (w), 2160 (m), 2028 (m), 1978 (m), 1646 (s), 1561 (w), 1459 (w), 1396 (w), 1378 (w), 1333 (s), 1279 (m), 1212 (s), 1152 (w), 1067 (w), 1039 (w), 1006 (w), 972 (w), 919 (w), 816 (m), 759 (m), 759 (w), 732 (m), 701 (m), 653 (m), 620 (m). IR $(CH_2Cl_2, cm^{-1}) v_{max} 3020 (m), 2971 (m), 2937 (w), 2880 (w), 2005 (w), 2360 (w), 2342 (w), 1646, 1559 (m), 2880 (m), 2880 (m), 2980 (m),$ (w), 1522 (w), 1461 (w), 1436 (w), 1406 (w), 1393 (w), 1379 (m), 1336 (m), 1310 (w), 1284 (m), 1269 (s), 1217 1005 917 896 **ESI** (s), (w), (\mathbf{w}) , (m). $^{+}$ -MS m/z 527.2 (12%, [MNa] $^{+}$), 505.2 (100%, [MH] $^{+}$), 433.2 (1%), 209.2 (3%, [I t PeH] $^{+}$). ESI $^{+}$ -HRMS calcd. for $C_{17}H_{29}Au^{14}N_2^{15}NO_2$ ([MH]⁺) 505.1896; found 505.1891.

2.38 $[AuBr_2(^{15}N-succ)(I^tPe)](^{15}N-19a)$

[Au(¹⁵N-Succ)(I^tPe)] (72) (41.3 mg, 81.9 µmol, 1 equiv.) was dissolved in dichloromethane (2 ml) and bromine (14.4 mg, 90.0 µmol, 1.1 equiv.) was added dropwise. The yellow solution was stirred at room temperature for 1 hour. The volume was reduced to <0.5 ml in vacuo and hexane added resulting in a yellow precipitate. This was separated by filtration, washed (cold hexane and diethyl ether) and dried in vacuo to give the title compound as a yellow powder (51.1 mg, 70.0 μmol, 94%). ¹H NMR (400 MHz, CDCl₃) δ 7.36 (s, 2H, imidazole CH), 2.73 (s, 4H, succ CH₂), 2.06 {s, 12H, ^tPe C(CH₃)₂}, 2.04 (q, J = 7.5Hz, 4H, ^tPe CH₂CH₃), 0.84 (t, J = 7.5 Hz, 6H, ^tPe CH₂CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 183.9 (d, J =9 Hz, succ C=O), 132.8 (d, J = 25 Hz, carbene Au-C), 122.3 (imidazole CH), 65.6 (^tPe quaternary C), 37.0 (t Pe CH₂CH₃), 31.5 (d, J = 5 Hz, succ CH₂), 29.9 { t Pe C(CH₃)₂}, 8.7 (t Pe CH₂CH₃). 15 N NMR (50 MHz, CD₂Cl₂) δ 179.4 (s). IR (solid, cm⁻¹) v_{max} 2976 (s), 2165 (m), 2037 (m), 1662 (s), 1461 (m), 1419 (w), 1392 (w), 1331 (s), 1280 (m), 1211 (s), 1164 (m), 1065 (w), 1002 (w), 809 (m). IR (CH₂Cl₂, cm⁻¹) v_{max} 2978 (m), 2941 (w), 2881 (w), 1744 (w), 1702 (w), 1662 (s), 1583 (w), 1481 (w), 1464 (w), 1413 (w), 1385 (w), 1337 (m), 1283 (w), 1216 (m), 1176 (w), 1163 (w), 1151 (w), 1066 (w), 1035 (w), 1003 (w). $ESI^{+}-MS \ m/z \ 728.0 \ (2\%, [MNa+MeCN]^{+}), 687.0 \ (5\%, [MNa]^{+}), 665.0 \ (100\%, [MH]^{+}), 610.2 \ (1\%), 591.3$ (3%), 536.2 (3%), 505.2 (2%, [MH-2Br]⁺), 401.0 (5%), 287.1 (38%, [I^tPeBr]⁺), 209.2 (51%, [I^tPeH]⁺), 176.4 (3%). ESI⁺-HRMS calcd. for C₁₇H₂₉AuBr₂¹⁴N₂¹⁵NO₂ ([MH]⁺) 665.0242; found 665.0232.

3.0 1,5-Enyne cycloisomerization catalysis

3.1 General procedure for the cycloisomerization of 4-phenyl-1-hexen-5-yne (24) – without catalyst preformation

To a solution of 4-phenyl-1-hexen-5-yne (24) (50.0 mg, 321 μ mol, 1 equiv.) in CH₂Cl₂ (0.64 mL, 0.50 M), AgOTf (0.8 mg, 3.1 μ mol, 0.01 equiv.) and gold complex (3.2 μ mol, 0.01 equiv.) were added. The solution was stirred at 25 °C for 3 hours and filtered through a plug of silica-gel which was washed with CH₂Cl₂ (2 ml). The solution was reduced *in vacuo* and conversion was determined by ¹H NMR spectroscopy. For characterization purposes the product can be purified by column chromatography on silica-gel using petroleum ether (40-60 °C) as eluent (R_f = 0.76). Fractions containing the product were combined and reduced *in vacuo* to give the title product (25) as a white powder.

3.2 General procedure for the cycloisomerization of 4-phenyl-1-hexen-5-yne (24) – with catalyst preformation

The test Au complex (3.2 μmol, 0.01 equiv.) and AgOTf (0.8 mg, 3.2 μmol, 0.01 equiv.) were mixed in dichloromethane in a screw cap vial (1 min) and the solvent removed *in vacuo*. A solution of 4-phenyl-1-hexen-5-yne (24) (50.0 mg, 321 μmol, 1 equiv.) in 1,2-dichloroethane (1.60 ml, 0.20 M) was added, the vial sealed with a rubber septum and a positive pressure of argon applied *via* an argon balloon. The mixture was stirred at 25 °C in the absence of light. Samples (10 μl) were taken *via* syringe and added immediately to a solution of tetra-*n*-butylammonium chloride (8 mM, 20 μl; 'quench') in CH₂Cl₂. Conversion was determined *via* gas chromatography using a 1 μl sample (and cross-checked by ¹H NMR spectroscopic analysis). The chromatogram was run with an injector temperature of 250 °C and an initial oven temperature of 80 °C (0.5 mins), heated to 160 °C, at a rate of 20 °C.min⁻¹, and maintained at 160 °C (1 minute). The retention times were: 2.58 minutes for 4-phenyl-1-hexen-5-yne (24) and 3.89 minutes for 3-phenylbicyclo[3.1.0]hex-2-ene (25), and both compounds exhibit the same response factor (confirmed by ¹H NMR spectroscopic analysis).

3.3 4-Phenyl-1-hexen-5-yne (24)

1-Phenyl-prop-2-yn-1-ol (2.53 ml, 20.4 mmol, 1 equiv.) and allyltrimethylsilane (9.78 ml, 61.4 mmol, 3 equiv.) were mixed in acetonitrile (40 ml, dry). FeCl₃ (anhydrous, 166 mg, 1.02 mmol, 0.05 equiv.) in acetonitrile (5 ml, dry) was added dropwise. The reaction was stirred (2 hours, r.t.). FeCl₃ (anhydrous, 166 mg, 1.02 mmol, 0.05 equiv.) in dry acetonitrile (5 ml dry) was added dropwise and the reaction stirred (1

hour, r.t.). The solution was reduced *in vacuo* and the product was purified by column chromatography, eluting with 100% petroleum ether (40-60), to give the title compound as a colourless oil (2.70 g, 17.3 mmol, 85%). ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.32 (m, 4H), 7.29-7.24 (m, 1H), 5.87 (ddtd, J = 17.1, 10.2, 7.0 and 1.3 Hz, 1H), 5.13-5.06 (m, 2H), 3.72 (td, J = 7.2 and 2.4 Hz, 1H), 2.54 (t, J = 7.2 Hz, 2H), 2.32 (app. d, J = 2.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 140.7, 135.1, 128.5, 127.4, 126.9, 117.1, 85.3, 71.4, 42.4, 37.6. EI⁺-MS m/z 156 (4%, [M]⁺), 155 (7%), 141 (8%, [M-CH₃]⁺), 128 (6%, [M-C₂H₄]⁺), 115 (100%, [M-allyl]⁺), 91 (6%), 89 (8%), 65 (3%), 63 (5%). EI⁺-HRMS calcd. for. C₁₂H₁₂ ([M]⁺) 156.0939; found 156.0943.

3.4 3-Phenylbicyclo[3.1.0]hex-2-ene (25)

¹H NMR (400 MHz, CDCl₃) δ 7.45-7.42 (m, 2H), 7.38-7.33 (m, 2H), 7.26 (m, 1H), 6.48 (q, J = 2 Hz, 1H), 3.08 (ddd, J = 17, 7.5 and 2 Hz, 1H), 2.80 (app. d, J = 17 Hz, 1H), 2.01 (m, 1H), 1.79 (m, 1H), 1.00 (td, J = 7.5 and 4 Hz, 1H), 0.17 (dd, J = 7 and 4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 139.7, 136.6, 129.6, 128.2, 126.7, 125.1, 36.3, 23.8, 17.6, 15.4. EI⁺-MS 156 (100%, [M]⁺), 141 (56%), 128 (39%), 115 (43%), 102 (7%), 91 (18%), 77 (12%), 63 (5%), 51 (6%). EI⁺-HRMS calcd. for C₁₂H₁₂ ([M]⁺) 156.0939; found 156.0934.

4.0 X-Ray Crystallographic Data

Diffraction data were collected at 110 K on a Bruker Smart Apex diffractometer with Mo- K_{α} radiation (λ = 0.71073 Å) using a SMART CCD camera. Diffractometer control, data collection and initial unit cell determination was performed using "SMART" (v5.625 Bruker-AXS). Frame integration and unit-cell refinement software was carried out with "SAINT+" (v6.22, Bruker AXS). Absorption corrections were applied by SADABS (v2.03, Sheldrick). Structures were solved by direct methods using SHELXS-97 (Sheldrick, 1990) and refined by full-matrix least squares using SHELXL-97 (Sheldrick, 1997). All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were placed using a "riding model" and included in the refinement at calculated positions.

A summary of X-ray data is given below in tabular form, for both series of Au(I) and Au(III) complexes. The data for complex **19c** has been previously reported by our group.⁴

Table S1 Summary of all the X-ray data detailed in the paper.

Compound reference	ijf0802 (20c)	ijf0805m (18a)	ijf0806a (18e)	ijf0807a (11d)	ijf0918m (19a)	vc0801m (13a)	vc0802m (11a)
Chemical formula	C ₂₉ H ₂₈ AuBr ₂ N ₃ O ₂ • C ₆ H ₅ F	$C_{15}H_{24}AuBr_2N_3O_2$	$C_{19}H_{24}AuBr_2N_3O_2$	C ₁₉ H ₂₄ AuN ₃ O ₂	2(C ₁₇ H ₂₈ AuBr ₂ N ₃ O ₂)•C ₆ H ₅ F	C ₂₅ H ₂₈ AuN ₃ O ₂	$C_{15}H_{24}AuN_3O_2$
Formula Mass	903.43	635.16	683.20	523.38	1422.52	599.47	475.34
Crystal system	Monoclinic	Triclinic	Orthorhombic	Orthorhombic	Triclinic	Monoclinic	Orthorhombic
a/Å	17.6109(3)	9.7911(5)	19.8674(17)	11.8766(6)	11.8901(9)	9.6744(4)	11.3451(8)
b/Å	12.2187(3)	13.9362(7)	13.3922(11)	17.1592(9)	14.8899(11)	20.2249(9)	10.6675(7)
c/Å	16.6542(3)	15.3479(8)	8.3251(7)	9.4378(5)	15.2604(12)	12.7004(6)	27.4051(19)
α/°	90.00	72.3520(10)	90.00	90.00	106.6900(10)	90.00	90.00
β/°	111.8490(10)	74.0220(10)	90.00	90.00	107.2830(10)	109.8040(10)	90.00
γ/°	90.00	86.4790(10)	90.00	90.00	96.2640(10)	90.00	90.00
Unit cell volume/Å ³	3326.26(12)	1918.02(17)	2215.0(3)	1923.36(17)	2414.6(3)	2338.04(18)	3316.7(4)
Temperature /K	120(2)	110(2)	110(2)	110(2)	110(2)	110(2)	110(2)
Space group	P2(1)/c	P1	Pnma	Pnma	P1	P2(1)/c	Pca2(1)
No. of formula units per unit cell, Z	4	4	4	4	2	4	8
No. of reflections measured	44337	22084	20843	14707	27421	26386	33945
No. of independent reflections	7619	10877	2847	2870	13566	6750	8208
R_{int}	0.0509	0.0333	0.0546	0.0309	0.0261	0.0280	0.0349
Final R_I values $(I > 2\sigma(I))$	0.0285	0.0307	0.0319	0.0200	0.0247	0.0229	0.0213
Final $wR(F^2)$ values $(I > 2\sigma(I))$	0.0581	0.0654	0.0845	0.0441	0.0617	0.0525	0.0450
Final R ₁ values (all data)	0.0401	0.0421	0.0352	0.0246	0.0300	0.0271	0.0282
Final wR(F ²) values (all data)	0.0613	0.0688	0.0871	0.0456	0.0639	0.0540	0.0472

5.0 References

- (3) Jafarpour, L.; Stevens, E. D.; Nolan, S. P. J. Organomet. Chem. 2000, 606, 49-54.
- (4) Reeds, J. P.; Whitwood, A. C.; Healy, M. P.; Fairlamb, I. J. S. Chem. Commun. 2010, 46, 2046-2048.

⁽¹⁾ Unresolved due to complicated higher order spin-spin coupling (¹³C-¹⁹F).

⁽²⁾ De Frémont, P.; Singh, R.; Stevens, E. D.; Peterson, J. L.; Nolan, S. P. *Organometallics* **2007**, *26*, 1376-1385.